Isoniazid
- PDF / 169,775 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 75 Downloads / 158 Views
1 S
Acquired resistance and lack of efficacy: 7 case reports In a retrospective observational study of patients, who were treated for tuberculosis between January 2006 and December 2018, 7 patients [ages and sexes not stated] were described, who acquired resistance to isoniazid while being treated for tuberculosis. Additionally, two of these 7 patients exhibited lack of efficacy and died eventually due to meningeal tuberculosis during treatment with isoniazide, rifampicin, pyrazinamide, ethambutol, moxifloxacin, amikacin, ethionamide or cycloserine for tuberculosis [dosages and routes not stated]. Six of these 7 patients were diagnosed with pulmonary tuberculosis infection, while the remaining one patient was diagnosed with extrapulmonary tuberculosis infection. Six of these 7 patients received standard treatment for tuberculosis in Colombia comprising isoniazid and concomitant rifampicin, pyrazinamide and ethambutol. During the course of the treatment, the patients were identified to have acquired monoresistance to isoniazid. One of these six patients subsequently received treatments with moxifloxacin, amikacin, ethionamide, cycloserine, isoniazid, rifampicin, ethambutol and pyrazinamide followed by moxifloxacin, amikacin, cycloserine, pyrazinamide and isoniazid for the tuberculosis. However, the patient exhibited lack of efficacy and eventually died due to meningeal tuberculosis. Another patient received treatments with isoniazid, rifampicin, ethambutol and pyrazinamide followed by isoniazide and rifampicin for the tuberculosis. During the course of the treatment, the patient was identified to have developed primary resistance to isoniazid. Thereafter, the patient exhibited lack of efficacy to the anti-tubercular drugs and died eventually due to meningeal tuberculosis. Garcia-Goez JF, et al. An appraisal of the isoniazid resistant tuberculosis in Colombia: A underestimated problem in Colombia?. Infectio 24: 173-181, No. 3, 2020. Available from: URL: http://doi.org/10.22354/in.v24i3.863 [Spanish; summarised from a translation] 803506941
0114-9954/20/1826-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 17 Oct 2020 No. 1826
Data Loading...
